Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: quidditch who wrote (9015)	11/18/2005 12:37:49 PM
From: quidditch	Read Replies (1) of 10280

LONDON, Nov 18 (Reuters) - Europe's biggest drugmaker GlaxoSmithKline (GSK.L - news) said on Friday it disagreed with the changes to the labelling of two of its asthma drugs proposed by U.S. drug administrators. GSK said the FDA's proposals for Serevent and Advair were inconsistent with the standard of care for asthma treatment, which could put many patients at risk of uncontrolled asthma. "These proposed labeling changes would reserve the most effective asthma treatment - the combination of inhaled corticosteroids and long-acting beta agonists - until after a patient has failed on other treatment options and therefore may be at risk for severe outcomes, such as exacerbations and potentially death," GSK said in a statement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next